Market Closed -
Nasdaq
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
2.98
USD
|
+5.30%
|
|
+3.11%
|
+58.92%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
271.4
|
75.84
|
30.2
|
21.31
|
61.32
|
-
|
-
|
Enterprise Value (EV)
1 |
271.4
|
75.84
|
30.2
|
21.31
|
61.32
|
61.32
|
61.32
|
P/E ratio
|
-5.15
x
|
-1.6
x
|
-0.46
x
|
-0.53
x
|
-0.95
x
|
-0.97
x
|
-0.89
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1.73
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1.73
x
|
EV / EBITDA
|
-7,925,679
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-11.2
x
|
-2.16
x
|
-
|
-
|
-1.47
x
|
-0.78
x
|
-1.42
x
|
FCF Yield
|
-8.96%
|
-46.3%
|
-
|
-
|
-67.8%
|
-128%
|
-70.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,212
|
11,236
|
11,267
|
11,365
|
20,578
|
-
|
-
|
Reference price
2 |
24.21
|
6.750
|
2.680
|
1.875
|
2.980
|
2.980
|
2.980
|
Announcement Date
|
11/03/21
|
09/03/22
|
08/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
35.38
|
EBITDA
|
-
|
-34.25
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.83
|
-34.44
|
-47.49
|
-37.54
|
-43.61
|
-52.88
|
-68.58
|
-59.21
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-167.37%
|
Earnings before Tax (EBT)
1 |
-
|
-33.98
|
-47.25
|
-65.95
|
-40.42
|
-52.35
|
-59.94
|
-71.85
|
Net income
1 |
-
|
-33.98
|
-47.25
|
-65.95
|
-40.42
|
-51.67
|
-60.33
|
-66.88
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-189.05%
|
EPS
2 |
-
|
-4.700
|
-4.210
|
-5.860
|
-3.570
|
-3.145
|
-3.078
|
-3.333
|
Free Cash Flow
1 |
-
|
-24.32
|
-35.1
|
-
|
-
|
-41.58
|
-78.48
|
-43.09
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-121.81%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/21
|
11/03/21
|
09/03/22
|
08/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.29
|
-10.87
|
-8.705
|
-7.974
|
-9.992
|
-9.732
|
-12.14
|
-10.7
|
-11.04
|
-11.85
|
-13.18
|
-13.6
|
-14.2
|
-15.3
|
-15.62
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.23
|
-10.76
|
-8.539
|
-7.691
|
-38.97
|
-9.045
|
-11.29
|
-9.86
|
-10.22
|
-11.1
|
-13.4
|
-13.62
|
-14.23
|
-15.15
|
-15.47
|
Net income
1 |
-10.23
|
-10.76
|
-8.539
|
-7.691
|
-38.97
|
-9.045
|
-11.29
|
-9.86
|
-10.22
|
-11.1
|
-13.08
|
-13.43
|
-14.06
|
-15.15
|
-15.47
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9100
|
-0.9600
|
-0.8000
|
-0.6800
|
-3.460
|
-0.8000
|
-1.000
|
-0.8700
|
-0.9000
|
-0.9700
|
-0.7375
|
-0.7625
|
-0.7900
|
-0.7550
|
-0.7750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/03/22
|
05/05/22
|
09/08/22
|
03/11/22
|
08/03/23
|
04/05/23
|
03/08/23
|
03/11/23
|
13/03/24
|
02/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-24.3
|
-35.1
|
-
|
-
|
-41.6
|
-78.5
|
-43.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.88
|
0.6
|
-
|
-
|
0.79
|
0.87
|
0.96
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.71%
|
Announcement Date
|
11/03/21
|
11/03/21
|
09/03/22
|
08/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
2.98
USD Average target price
27.8
USD Spread / Average Target +832.89% Consensus |
1st Jan change
|
Capi.
|
---|
| +58.92% | 61.32M | | +2.97% | 108B | | +10.21% | 104B | | +2.88% | 22.33B | | -12.77% | 22.19B | | -7.05% | 18.69B | | -37.64% | 17.74B | | -6.50% | 17.64B | | +6.00% | 14.05B | | +37.20% | 12.51B |
Bio Therapeutic Drugs
|